The role of the polyamine inhibitor eflornithine in the neuropathogenesis of experimental murine African trypanosomiasis

Neuropathology and Applied Neurobiology

Volumn 23, Issue 3, 1997, Pages 225-234

  Jennings, F W ^a   Gichuki, C W ^a,c   Kennedy, P G E ^a,b   Rodgers, J ^a   Hunter, C A ^a,d   Murray, M ^a   Burke, J M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c Kenya Trypanosomiasis Research Institute   (Kenya)

^d PALO ALTO MEDICAL FOUNDATION RESEARCH INSTITUTE   (United States)

Author keywords

Astrocytes; Eflornithine; Histopathology; Immunocytochemistry; Inflammation; Trypanosomiasis

Indexed keywords

DIMINAZENE ACETURATE; EFLORNITHINE;

AFRICAN TRYPANOSOMIASIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN DISEASE; ENCEPHALITIS; FEMALE; HISTOPATHOLOGY; IMMUNOCYTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; MENINGOENCEPHALITIS; MOUSE; NEUROPATHOLOGY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030920739     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2990.1997.tb01206.x     Document Type: Article

References (31)

1. Adams H, Doua A, Dago-Akribi A, Boa Y, Haller L. Human African trypanosomiasis (T b gambiense): a study of 16 cases of sleeping sickness with some observations on acute reactive arsenical encephalopathy. Neuropathol Appl Neurobiol 1986; 12: 81-94
2. Arroz JOL. Melarsoprol and reactive encephalopathy in Trypanosoma brucei rhodesiense. Trans R Soc Trop Med Hyg 1987; 81: 192
3. Bacchi C, Nathan CH, Hutner SH et al. Polyamine metabolism. A potential therapeutic target in trypanosomes. Science 1980; 210: 332-4
4. Bacchi CJ, Nathan HC, Livingston T et al. Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense. Antimicrob Ag Chem 1990; 34: 1183-8
5. Bitonti AJ, McCann PP, Sjoerdsma A. Necessity of antibody response with treatment of African trypanosomiasis with alpha-difluoromethylornithine. Biochem Pharm 1986; 35: 331-4
6. de Gee ALW, McCann PP, Mansfield JM. Role of antibody in the elimination of trypanosomes after DL-alpha difluoromethylornithine chemotherapy. J Parasitol 1983; 69: 818-22
7. Epidemiology and control of African trypanosomiasis. Geneva: WHO Tech Rep Ser no. 739, Geneva, 1986
8. Haller L, Adams H, Merowze F, Dago A. Clinical and pathological aspects of human African trypanosomiasis (T b gambiense) with particular reference to reactive arsenical encephalopathy. Am J Trop Med Hyg 1986; 5: 94-9
9. Hunter CA, Cow JW, Jennings FW, Kennedy PGE, Murray M. Immunopathology of experimental African sleeping sickness: detection of cytokine mRNA in the brains of Trypanosoma brucei infected mice. Infect Immun 1991; 59: 4636-40
10. Hunter CA, Jennings FW, Adams JH, Murray M, Kennedy PGE. Sub-curative chemotherapy and fatal post-treatment reactive encephalopathies in African trypanosomiasis. Lancet 1992; 339: 956-8
11. Hunter CA, Jennings FW, Kennedy PGE, Murray M. Astrocyte activation correlates with cytokine production in central nervous system of Trypanosoma brucei brucei-infected mice. Lab Invest 1992; 67: 635-42
12. Hunter CA, Jennings FW, Kennedy PGE, Murray M. The use of azathioprine to ameliorate post-treatment encephalopathy associated with African trypanosomiasis. Neuropathol Appl Neurobiol 1992; 18: 619-25
13. Hurst EW. The lesions produced in the central nervous system by certain organic arsenical compounds. J Path Bact 1959; 77: 522-33
14. Jennings FW, Gray GD. Relapsed parasitaemia following chemotherapy of chronic Tryponosoma brucei infection in mice and its relation to cerebral trypanosomes. Contrib Microbiol Immunol 1983; 7: 147-54
15. Jennings FW, McNeil PE, Ndung'u JM, Murray M. Trypanosomiasis and encephalitis: possible aetiology and treatment. Trans R Soc Trop Med Hyg 1989; 83: 518-9
16. Jennings FW, Whitelaw DD, Urquhart GM. The relationship between duration of infection with Trypanosoma brucei in mice and the efficacy of chemotherapy. Parasitology 1977; 75: 143-53
17. Jennings FW. The potentiation of arsenicals with difluoromethylornithine (DFMO): experimental studies in murine trypanosomiasis. Bull Soc Path Ex 1988; 81: 595-607
18. Levin VA, Chamberlain MC, Prados MD et al. Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors. Cancer Treat Rep 1987; 71: 459-64
19. McCann PP, Bacchi CJ, Clarkson AB, Jr et al. Further studies on difluoromethylornithine in African trypanosomes. Med Biol 1981; 59: 434-40
20. Metcalf BW, Bey P, Danzin C, Jung MJ, Casara P, Vevert JP. Catalytic irreversible inhibition of mammalian ornithine decarboxylase by substrate and product analogues. J Am Chem Soc 1978; 100: 2551-3
21. Milord F, Pepin J, Loko L, Ethier L, Mpia B. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet 1992; 340: 652-5
22. Ormerod WE. Pathogenesis and pathology of trypanosomiasis in man. In: The African Trypanosomiasis, Ed Mulligan HW, London: Allen and Unwin/Ministry of Overseas Development, 1971: 588-601
23. Pepin J, Milord F, Guern C, Mpia B, Ethier L, Mansina D. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Lancet 1989; i: 1246-50
24. Pepin J, Milord F. African trypanosomiasis and drug induced encephalopathy: risk factors and pathogenesis. Trans R Soc Trop Med Hyg 1991; 85: 222-4
25. Poltera AA. Immunopathological and chemotherapeutic studies in experimental trypanosomiasis with special reference to the heart and brain. Trans R Soc Trop Med Hyg 1980; 74: 706-15
26. Poltera AA. Pathology of human African trypanosomiasis with reference to experimental African trypanosomiasis and infections of the central nervous system. Br Med Bull 1985; 164: 169-74
27. Sjoerdsma A, Scheeler PJ. Chemotherapeutic implications of polyamine biosynthesis inhibition. Clin Pharmacol Therap 1984; 35: 287-300
28. Van Nieuwenhove S, Schecter PJ, Declercq J, Bone G, Burke J, Sjoerdsma A. Treatment of gambian sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase: first field trail. Trans R Soc Trop Med Hyg 1985; 79: 692-8
29. Veeken HJGM, Ebeling MCA, Dolmans WMV, Trypanosomiasis in a rural hospital in Tanzania. A retrospective study of its management and the results of treatment. Trop Geogr Med 1989; 41: 113-7
30. WHO Sleeping sickness 'Resurrection' drug approved. WHO News No. 34, Dec. 1990
31. Zini I, Zoli M, Grimaldi R, Pich EM, Biagini G, Fuxe K, Agnati LF. Evidence for a role of neosynthetized putrescine in the increase of glial fibrillary acidic protein immunoreactivity induced by a mechanical lesion in the rat brain. Neurosci Lett 1990; 120: 13-6